Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Mentors in Medicine Series on Applied Precision Medicine: Focus on AML in Elderly Patients Beyond Chemotherapy
Release Date: April 1, 2021
Expiration Date: April 1, 2022
Activity Overview
This online, on-demand, case-based, CME-certified webcast brings together renowned experts in the treatment of acute myeloid leukemia (AML). It provides guidance for practicing oncologists on how to incorporate biomarker testing into everyday clinical practice to determine diagnosis and inform treatment selection for their patients with AML. The panel analyzes recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case includes an expert analysis of Show Me the Data® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.
This educational activity is an archive of the live virtual webcast held on March 25, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is intended for hematologists and oncologists involved in the treatment of patients with AML. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of AML are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing into diagnosis and/or therapy selection for treatment of patients with AML
- Analyze recent data on the efficacy and safety of therapeutic options for the treatment of patients with AML
- Apply optimal management strategies in the treatment of patients with AML based on recent clinical trial findings
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Series Chair
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
Hackensack, NJ
Disclosures: Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen, Karyopharm, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen, Kite Pharma, Xcenda; Stock/Shareholder: COTA; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen, Kite Pharma.
Moderator
Attending Physician
Division of Leukemia
John Theurer Cancer Center
Hackensack, NJ
Disclosures: Consultant: Pfizer; Speaker’s Bureau: AbbVie, Alexion, Amgen, Bristol Myers Squibb, Jazz Pharmaceuticals, Novartis.
Faculty
McCredie Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AbbVie, APR Applied Pharma Research, Astex, Bristol Myers Squibb, Curis, Genentech, Gilead Sciences, Novartis.
Director of Leukemia
Assistant Professor
Georgetown University Medical Center
Lombardi Comprehensive Cancer Center
Washington, DC
Disclosures: Consultant: AbbVie, Agios, Astellas, Genentech, Jazz Pharmaceuticals, MacroGenics; Speaker’s Bureau: Astellas, Jazz Pharmaceuticals.
Chief of Staff
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Advisory Board: AbbVie, Actinium Pharmaceuticals, Aprea Therapeutics, Arog Pharmaceuticals, BerGenGio, ElevateBio, Foghorn Therapeutics, GEMoaB, GSK, Innate Pharma, Jazz Pharmaceuticals, Onconova Therapeutics, Syndax Pharmaceuticals, Syros, Takeda; DSMB: Syntrix/ACI Clinical, Takeda; Steering Committee: AbbVie.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
